GlobeNewsWire
17 Nov 2025, 12:30 UTC · 45w ago
Verdict
Headline takes no side. We score BWAY +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
BrainsWay has launched the first multicenter clinical trial for its next-generation Deep TMS 360™ system, targeting Alcohol Use Disorder (AUD).
More positive than 98% of claims this week
The Deep TMS 360™ system features a novel multichannel architecture designed to provide more uniform brain stimulation, potentially overcoming cortical atrophy in chronic AUD patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 86% of claims this week
The randomized, sham-controlled trial will enroll over 200 patients across multiple U.S. and international sites with a primary endpoint of no heavy drinking days over four months.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company launched a first-of-its-kind multicenter clinical trial for its next-generation Deep TMS 360 system to treat Alcohol Use Disorder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+58.6%
Price agrees with the score
$12.50 vs $7.88 close before publication (Nov 14) · not market-adjusted
BWAY chart →
